Yunhui Wu
Pharmaceutical Research and Development
Merck Research Laboratories
West Point
PA 19486
USA
Name/email consistency: high
- The role of biopharmaceutics in the development of a clinical nanoparticle formulation of MK-0869: a Beagle dog model predicts improved bioavailability and diminished food effect on absorption in human. Wu, Y., Loper, A., Landis, E., Hettrick, L., Novak, L., Lynn, K., Chen, C., Thompson, K., Higgins, R., Batra, U., Shelukar, S., Kwei, G., Storey, D. Int. J. Pharm (2004)
- The importance of chromatographic separation in LC/MS/MS quantitation of drugs in biological fluids: detection, characterization, and synthesis of a previously unknown low-level nitrone metabolite of a substance P antagonist. Wu, Y., Farrell, J.T., Lynn, K., Euler, D., Kwei, G., Hwang, T.L., Qin, X.Z. Anal. Chem. (2003)
- Identification of oxidative degradates of the TRIS salt of a 5,6,7,8-tetrahydro-1,8-naphthyridine derivative by LC/MS/MS and NMR spectroscopy--interactions between the active pharmaceutical ingredient and its counterion. Wu, Y., Hwang, T.L., Algayer, K., Xu, W., Wang, H., Procopio, A., DeBusi, L., Yang, C.Y., Matuszewska, B. J. Pharm. Biomed. Anal (2003)
- Detection of oxidative species for 4-phenoxyphenol derivatives during the electrospray ionization process. Wu, Y., Wang, H. Rapid Commun. Mass Spectrom. (2000)
- Identification of oxidative degradates of the thrombin inhibitor, 3-(2-phenethylamino)-6-methyl-1-(2-amino-6-methyl-5-methyleneca rboxamidomethylpyridinyl)pyrazinone, using liquid chromatography/mass spectrometry and liquid chromatography/tandem mass spectrometry. Wu, Y., Chen, X., Gier, L., Almarsson, O., Ostovic, D., Loper, A.E. J. Pharm. Biomed. Anal (1999)
